(Note: For PDF File Swipe To The End Of Article)
1. Introduction
Urinary tract infection (UTI) is one of the most common bacterial infections encountered in clinical practice. It may involve any part of the urinary system, including the urethra, urinary bladder, ureters, and kidneys. Clinically, UTIs range from localized cystitis, which primarily affects the bladder, to systemic infections such as pyelonephritis, which may be associated with fever, chills, flank pain, bacteremia, and sepsis. The 2026 European Association of Urology (EAU) guideline emphasizes distinguishing localized UTI from systemic UTI because the choice and route of antimicrobial treatment depend greatly on the site and severity of infection.
The principal objective of pharmacological treatment is to eradicate the causative microorganism, relieve symptoms, prevent progression of infection, and reduce the risk of recurrence and complications. Antibiotic selection should not be based simply on the presence of urinary symptoms. It should take into consideration the clinical presentation, likely causative organism, local antimicrobial-resistance patterns, previous urine cultures, renal function, allergies, pregnancy status, drug interactions, and whether the infection is localized or systemic.
The most common pathogen responsible for community-acquired UTI is Escherichia coli, although other Enterobacterales, Klebsiella species, Proteus species, Enterococcus species, and other organisms may also cause infection. Increasing antimicrobial resistance has made appropriate antibiotic selection increasingly important. The 2025 IDSA guideline for complicated UTI recommends considering disease severity, previous resistant organisms, previous antibiotic exposure, patient-specific factors, and local susceptibility data when selecting empiric therapy.
Drugs used in UTI can broadly be divided into antibiotics for lower urinary tract infection, antibiotics appropriate for upper or systemic infection, and agents used for specific resistant organisms or special clinical situations. Some drugs are effective for bladder infection because they achieve high urinary concentrations but should not be used for kidney infection because they do not achieve adequate concentrations in renal tissue.
2. Principles of Antimicrobial Therapy in UTI
The selection of an antimicrobial agent should begin with an assessment of the clinical syndrome. A patient with dysuria, urinary frequency, urgency, and suprapubic discomfort without fever or flank pain may have localized cystitis. In contrast, fever, chills, flank pain, systemic illness, nausea, vomiting, or signs of sepsis suggest an upper or systemic UTI and require a different therapeutic approach.
For localized cystitis in women, current EAU recommendations identify fosfomycin, nitrofurantoin, pivmecillinam, and nitroxoline as first-line options where available. Trimethoprim-sulfamethoxazole and selected cephalosporins may be alternatives depending on susceptibility and local resistance patterns. Fluoroquinolones and aminopenicillins are not recommended for routine treatment of cystitis because of resistance, ecological effects, and stewardship considerations.
For systemic UTI or pyelonephritis, drugs must reach effective concentrations in the bloodstream and renal tissues. Consequently, nitrofurantoin, oral fosfomycin, and pivmecillinam should not be used to treat pyelonephritis. Depending on the clinical situation and susceptibility results, fluoroquinolones, selected cephalosporins, trimethoprim-sulfamethoxazole, and intravenous agents may be used.
Urine culture and antimicrobial susceptibility testing become particularly important in systemic infections, recurrent infections, treatment failure, pregnancy, suspected resistant organisms, and complicated clinical situations. Once culture results become available, therapy should generally be narrowed to an effective antimicrobial with an appropriate spectrum rather than continuing unnecessarily broad empiric treatment.
3. Nitrofurantoin
Nitrofurantoin is a urinary antimicrobial that is widely used for the treatment of acute uncomplicated cystitis. It is particularly useful because it achieves high concentrations in urine while having limited systemic distribution. Its mechanism involves bacterial reduction of nitrofurantoin metabolites that damage bacterial DNA and other cellular components.
Nitrofurantoin has activity against many common urinary pathogens, including susceptible E. coli, and remains an important option even in some infections caused by extended-spectrum β-lactamase (ESBL)-producing organisms. The 2026 IDSA antimicrobial-resistance guidance lists nitrofurantoin among preferred options for uncomplicated UTI caused by ESBL-producing Enterobacterales when the isolate is susceptible.
For uncomplicated cystitis in women, the EAU guideline lists nitrofurantoin monohydrate/macrocrystals at 100 mg twice daily for 5 days as a commonly recommended regimen. Exact formulation and dosing should follow the applicable local guideline and product information.
Nitrofurantoin is particularly useful for lower UTI but should not be selected for pyelonephritis because urinary concentration alone is insufficient when infection involves the renal parenchyma. The drug is also unsuitable when renal function is severely reduced. The EAU guideline identifies an estimated GFR below 30 mL/min/1.73 m² as a contraindication because reduced renal excretion can increase adverse effects while decreasing urinary effectiveness.
Common adverse effects include nausea, vomiting, abdominal discomfort, and headache. Taking the medication with food may improve gastrointestinal tolerance. Rare but important adverse reactions include pulmonary toxicity, hepatotoxicity, and peripheral neuropathy, particularly with prolonged exposure.
Nitrofurantoin should therefore be regarded primarily as a lower-UTI drug rather than a general-purpose UTI antibiotic.
4. Trimethoprim–Sulfamethoxazole (Co-trimoxazole)
Trimethoprim-sulfamethoxazole, commonly called co-trimoxazole or TMP-SMX, combines two antimicrobial agents that inhibit sequential steps in bacterial folate metabolism. Sulfamethoxazole inhibits dihydropteroate synthase, whereas trimethoprim inhibits dihydrofolate reductase. The sequential blockade produces enhanced antibacterial activity.
TMP-SMX has historically been an important oral treatment for uncomplicated cystitis and remains useful when the causative organism is susceptible. It is also an important oral option for certain systemic UTIs and infections caused by resistant Enterobacterales when susceptibility is demonstrated. The 2026 IDSA guidance lists TMP-SMX among preferred options for uncomplicated ESBL-producing Enterobacterales UTI when active against the organism.
Resistance, however, can substantially limit empirical use. Previous urine-culture results and local resistance patterns should therefore be considered before selecting TMP-SMX empirically. For uncomplicated cystitis, the EAU guideline lists 160/800 mg twice daily for 3 days as an alternative regimen in appropriate women, while a longer course may be used in selected male or systemic infections according to the clinical situation.
Important adverse effects include rash, gastrointestinal symptoms, hyperkalemia, and increases in serum creatinine. Serious reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis are rare but potentially life-threatening. Bone-marrow suppression may occur, particularly with prolonged treatment or in susceptible patients.
Drug interactions are clinically important. TMP-SMX may increase the risk of hyperkalemia when combined with drugs that raise potassium concentrations and can potentiate the anticoagulant effect of warfarin. Renal function should be considered when determining the appropriate regimen.
During pregnancy, trimester-specific considerations are important because both trimethoprim and sulfonamides have particular restrictions. The EAU guideline advises avoiding trimethoprim during the first trimester and sulfonamides during the last trimester.
5. Fosfomycin
Fosfomycin is a broad-spectrum urinary antimicrobial with a unique mechanism of action. It inhibits an early step in bacterial cell-wall synthesis by blocking the MurA enzyme. Because its mechanism differs from that of most other antibiotics, fosfomycin can retain activity against some multidrug-resistant urinary pathogens.
Oral fosfomycin trometamol is particularly useful for uncomplicated cystitis. The EAU guideline lists 3 g as a single dose as a first-line treatment option for women with cystitis.
One of the major advantages of fosfomycin is its convenient dosing. A single oral dose can improve adherence compared with regimens requiring several doses per day for multiple days. It can also retain activity against some resistant organisms, although susceptibility should not be assumed automatically.
The 2026 IDSA guidance lists oral fosfomycin as an alternative treatment for uncomplicated UTI caused by ESBL-producing E. coli. Its role is more limited for organisms other than E. coli because resistance mechanisms and clinical efficacy vary.
Fosfomycin should not be used as routine oral therapy for pyelonephritis, because adequate renal tissue concentrations are not reliably achieved.
Adverse effects are generally mild and include diarrhea, nausea, abdominal discomfort, headache, and vaginal symptoms. However, inappropriate repeated use can contribute to resistance, so fosfomycin should be reserved for appropriate indications.
6. Ciprofloxacin
Ciprofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for bacterial DNA replication and chromosome segregation. It has excellent tissue penetration and can achieve therapeutic concentrations in the urinary tract and renal tissue.
Ciprofloxacin has historically been widely used for complicated UTI and pyelonephritis. It may still be appropriate for systemic UTI when the organism is susceptible and other suitable options are inappropriate. Current guidance, however, emphasizes antimicrobial stewardship and avoidance of unnecessary fluoroquinolone exposure.
The EAU guideline gives ciprofloxacin as an empirical oral option for pyelonephritis under appropriate resistance conditions, with susceptibility and local resistance patterns playing an important role.
Ciprofloxacin should not routinely be used for uncomplicated cystitis when safer, narrower alternatives are available. The EAU guideline specifically recommends against using fluoroquinolones for routine cystitis.
Important adverse effects include nausea, diarrhea, headache, dizziness, and central nervous system effects. More serious reactions include tendinitis and tendon rupture, peripheral neuropathy, QT-interval prolongation, dysglycemia, and other potentially disabling adverse effects.
Ciprofloxacin also has clinically important drug interactions. It can interact with certain antiarrhythmics, anticoagulants, antidiabetic agents, and other medications. Absorption may be reduced by polyvalent cations such as calcium, magnesium, aluminum, and iron.
Because of these safety considerations and the importance of preserving fluoroquinolone activity against resistant organisms, ciprofloxacin should be used selectively rather than automatically for every UTI.
7. Levofloxacin
Levofloxacin is another fluoroquinolone with activity against many Gram-negative urinary pathogens. It inhibits DNA gyrase and topoisomerase IV and has good penetration into urinary and renal tissues.
Levofloxacin can be used for selected cases of pyelonephritis or systemic UTI when the organism is susceptible and the patient's clinical circumstances support fluoroquinolone therapy. The EAU guideline includes levofloxacin among empirical oral options for pyelonephritis.
As with ciprofloxacin, levofloxacin should not be routinely selected for uncomplicated cystitis when effective first-line alternatives are available. Restricting fluoroquinolone use helps reduce unnecessary adverse effects and preserve these drugs for situations in which they provide an important therapeutic advantage.
Levofloxacin is generally administered once daily, which can make it convenient for selected patients. Dose adjustment is required in significant renal impairment because the drug is predominantly eliminated through the kidneys.
Potential adverse effects include gastrointestinal disturbances, dizziness, headache, insomnia, and hypersensitivity reactions. Serious fluoroquinolone-associated adverse effects can include tendon injury, peripheral neuropathy, central nervous system effects, QT prolongation, and disturbances of glucose regulation.
8. Amoxicillin–Clavulanate
Amoxicillin-clavulanate is a β-lactam/β-lactamase inhibitor combination. Amoxicillin interferes with bacterial cell-wall synthesis by binding penicillin-binding proteins, whereas clavulanate inhibits certain β-lactamases and thereby protects amoxicillin from enzymatic degradation.
The combination has activity against several urinary pathogens, but resistance varies substantially according to geographic region and bacterial species. It is therefore not universally appropriate as empirical therapy for every UTI.
Amoxicillin-clavulanate may be considered in selected patients when the causative organism is susceptible, particularly when culture and susceptibility results support its use. The 2025 IDSA complicated-UTI guideline notes that amoxicillin-clavulanate may be appropriate in selected settings for oral treatment of complicated UTI, although it is less well studied than some preferred empiric options.
The EAU guideline does not recommend aminopenicillins as routine first-line treatment for cystitis because of high resistance rates, ecological effects, and selection of ESBL-producing organisms.
Common adverse effects include diarrhea, nausea, vomiting, and abdominal discomfort. Allergic reactions may occur, ranging from mild rash to severe anaphylaxis. Antibiotic-associated diarrhea, including Clostridioides difficile infection, is an important potential complication of broad-spectrum antibiotic exposure.
9. Cefixime
Cefixime is an orally administered third-generation cephalosporin. Like other β-lactam antibiotics, it inhibits bacterial cell-wall synthesis by interfering with peptidoglycan cross-linking.
Cefixime can be used for selected urinary infections when the causative organism is susceptible. It may be considered particularly when first-line agents are unsuitable because of allergy, intolerance, resistance, pregnancy-related considerations, or other clinical factors.
However, oral cephalosporins should not automatically be considered interchangeable with intravenous cephalosporins. The EAU guideline notes that oral cephalosporins achieve different systemic and urinary concentrations compared with intravenous preparations, which is particularly relevant when treating pyelonephritis.
Cefixime is generally well tolerated. Common adverse effects include diarrhea, nausea, abdominal discomfort, and headache. Allergic reactions may occur, particularly in patients with previous severe β-lactam hypersensitivity.
Excessive use of third-generation cephalosporins can contribute to selection of resistant organisms, including ESBL-producing Enterobacterales. Therefore, cefixime should preferably be used when there is a clear clinical indication and, when appropriate, susceptibility information supports its use.
10. Ceftriaxone
Ceftriaxone is a third-generation cephalosporin administered parenterally. It inhibits bacterial cell-wall synthesis and has broad activity against many Gram-negative and Gram-positive organisms.
It is particularly useful in patients with systemic UTI, pyelonephritis, complicated infection, or severe illness when intravenous or intramuscular therapy is required. It may also be used as an initial parenteral agent when an oral treatment option is being considered but susceptibility or clinical circumstances make immediate oral therapy less appropriate.
The EAU guideline specifically describes an initial intravenous dose of a long-acting parenteral antimicrobial such as ceftriaxone in selected pyelonephritis patients when an alternative oral agent is being used empirically without susceptibility results.
Ceftriaxone is also included among antibiotic classes that may be prioritized for empiric treatment of complicated UTI with sepsis, although the final choice should be individualized according to severity, resistance risk, previous cultures, allergies, drug interactions, and local susceptibility data.
Common adverse effects include diarrhea, nausea, rash, and injection-site reactions. Biliary sludge or pseudolithiasis can occur, particularly with certain dosing patterns or prolonged treatment. Severe allergic reactions are uncommon but possible.
Ceftriaxone is generally reserved for situations where parenteral treatment is clinically justified rather than being used routinely for simple cystitis.
11. Pivmecillinam
Pivmecillinam is an oral β-lactam antimicrobial that is particularly useful against susceptible Gram-negative urinary pathogens. It is converted to mecillinam after administration and primarily acts against bacterial cell-wall synthesis.
The 2026 EAU guideline lists pivmecillinam as one of the first-line treatments for cystitis in women where it is available. A commonly listed regimen is 400 mg three times daily for 3–5 days.
Pivmecillinam has an important role in antimicrobial stewardship because it can provide an effective narrow-spectrum option for lower UTI while reducing unnecessary exposure to broader-spectrum antibiotics.
It should not be routinely used for pyelonephritis because adequate evidence for its efficacy in renal parenchymal infection is lacking.
Adverse effects are generally mild and may include gastrointestinal symptoms, nausea, diarrhea, and rash. Availability varies considerably between countries, so treatment recommendations depend on local formularies and guidelines.
12. Cephalosporins
Cephalosporins comprise several generations of β-lactam antibiotics with progressively different antibacterial spectra. They are used in UTI according to the suspected site of infection, organism, resistance pattern, and severity.
Oral cephalosporins such as cefixime and cefpodoxime may be used in selected urinary infections, while intravenous agents such as ceftriaxone and cefepime may be used for more severe or systemic infections.
For pyelonephritis, the EAU guideline lists selected cephalosporins as treatment options and emphasizes that oral cephalosporins have different pharmacokinetic characteristics from intravenous preparations.
Ceftriaxone is particularly useful in emergency and inpatient settings because of its long duration of action and convenient once-daily administration in many clinical circumstances.
Cefepime, a fourth-generation cephalosporin, has broader Gram-negative activity and can be useful for selected complicated UTIs, particularly when resistant organisms or Pseudomonas aeruginosa are concerns and susceptibility supports its use. The 2025 IDSA complicated-UTI guideline includes third- and fourth-generation cephalosporins among important empiric options for severe complicated UTI.
However, unnecessary use of broad-spectrum cephalosporins can promote antimicrobial resistance. Therapy should therefore be narrowed whenever culture results identify a more appropriate narrower-spectrum drug.
13. Aminoglycosides
Aminoglycosides such as gentamicin, amikacin, and tobramycin inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit. They are potent agents against many Gram-negative bacteria.
They can be useful in severe urinary infections, resistant Gram-negative infections, or situations in which other effective antibiotics cannot be used. The 2026 IDSA guidance includes a single-dose aminoglycoside as an alternative for selected uncomplicated resistant UTIs and recognizes aminoglycosides as alternatives for certain pyelonephritis and complicated UTI scenarios when other agents are unsuitable.
A major limitation is toxicity. Aminoglycosides can cause nephrotoxicity and ototoxicity, and risk increases with prolonged therapy, high exposure, renal impairment, dehydration, and concomitant nephrotoxic drugs.
Because they are primarily eliminated by the kidneys and have a narrow therapeutic margin, renal function and, when appropriate, serum drug concentrations must be monitored.
Aminoglycosides are therefore generally reserved for situations in which their benefits outweigh their toxicity risks rather than being used routinely for uncomplicated cystitis.
14. Carbapenems
Carbapenems are broad-spectrum β-lactam antibiotics that include ertapenem, meropenem, imipenem-cilastatin, and related agents. They inhibit bacterial cell-wall synthesis and are highly effective against many resistant Gram-negative organisms.
Carbapenems are particularly important in serious infections caused by ESBL-producing Enterobacterales and other highly resistant organisms. The 2026 IDSA guidance identifies carbapenems as alternatives for uncomplicated resistant UTI when preferred oral agents cannot be used and as important treatment options for resistant systemic infections.
Because carbapenems have very broad activity, their unnecessary use can promote further resistance. They should therefore generally be reserved for infections in which narrower agents are ineffective, inappropriate, or unavailable.
Ertapenem is convenient for many complicated urinary infections because of once-daily administration, whereas meropenem and imipenem-cilastatin have broader activity against certain difficult Gram-negative organisms.
Potential adverse effects include gastrointestinal symptoms, rash, hypersensitivity reactions, and, rarely, seizures, particularly with certain agents or in patients with significant renal impairment.
15. Piperacillin–Tazobactam
Piperacillin-tazobactam combines an extended-spectrum penicillin with a β-lactamase inhibitor. Piperacillin inhibits bacterial cell-wall synthesis, while tazobactam inhibits selected β-lactamases.
It has activity against many Gram-negative and Gram-positive organisms and also provides activity against Pseudomonas aeruginosa. Consequently, it may be used for severe complicated UTI and systemic urinary infections when the suspected pathogen and local resistance patterns make it appropriate.
The 2025 IDSA complicated-UTI guideline includes piperacillin-tazobactam among preferred empiric classes for patients with complicated UTI, particularly in severe illness, while emphasizing individualized assessment of resistance risk and patient-specific factors.
Piperacillin-tazobactam is administered intravenously. Dose adjustment may be necessary in renal impairment.
Adverse effects include diarrhea, nausea, rash, allergic reactions, electrolyte disturbances, and laboratory abnormalities. As with other broad-spectrum antibiotics, unnecessary exposure can contribute to antimicrobial resistance and disruption of normal microbiota.
16. Antibiotics for Resistant UTI
Antimicrobial resistance has become one of the major challenges in UTI management. Resistant organisms may include ESBL-producing Enterobacterales, AmpC-producing organisms, carbapenem-resistant Enterobacterales, multidrug-resistant Pseudomonas aeruginosa, and other difficult-to-treat pathogens.
The treatment of resistant UTI should ideally be based on urine culture and antimicrobial susceptibility testing. Previous urine cultures are also extremely valuable because they can indicate whether the patient has previously carried a resistant organism. The IDSA complicated-UTI guideline recommends avoiding antibiotics to which a patient previously had a resistant urinary isolate and considering recent fluoroquinolone exposure when choosing empiric therapy.
For ESBL-producing organisms causing uncomplicated cystitis, current IDSA guidance identifies nitrofurantoin and TMP-SMX among preferred options when susceptible, with fosfomycin as an alternative for E. coli. Fluoroquinolones and carbapenems may be effective but are generally reserved for situations in which preferred options cannot be used.
For resistant systemic UTI, treatment becomes more complex and may require intravenous broad-spectrum agents or newer β-lactam/β-lactamase inhibitor combinations. Selection should be guided by susceptibility testing, infection severity, previous antibiotic exposure, renal function, and source-control considerations.
17. Treatment of Pyelonephritis
Pyelonephritis is an infection involving the renal pelvis and renal parenchyma and should not be managed in the same manner as uncomplicated cystitis. Patients may present with fever, chills, flank pain, costovertebral-angle tenderness, nausea, vomiting, and systemic illness.
Urine culture and susceptibility testing are particularly important in pyelonephritis. The EAU guideline recommends obtaining urine culture and antimicrobial susceptibility testing and evaluating the urinary tract for potentially important structural or obstructive abnormalities.
Oral fluoroquinolones or selected cephalosporins may be used in appropriate patients, while trimethoprim-sulfamethoxazole may be used when susceptibility is established. Ceftriaxone and other intravenous agents may be required for patients with systemic illness or when an initial parenteral dose is clinically appropriate.
Nitrofurantoin, oral fosfomycin, and pivmecillinam should not be used as routine treatment for pyelonephritis because their pharmacokinetic properties do not provide reliable renal tissue treatment.
Patients who are severely ill, unable to tolerate oral medication, hemodynamically unstable, pregnant, immunocompromised, or suspected of having urinary obstruction may require hospital-based evaluation and intravenous therapy.
18. Drug Selection According to Site of UTI
The anatomical location of infection is one of the most important determinants of antibiotic selection.
For localized cystitis, drugs that achieve high urinary concentrations are particularly useful. Nitrofurantoin and fosfomycin are classic examples. Pivmecillinam and selected alternatives may also be appropriate depending on availability and susceptibility.
For pyelonephritis, the drug must penetrate renal tissue and achieve adequate systemic concentrations. Fluoroquinolones, selected cephalosporins, TMP-SMX when susceptible, and appropriate intravenous antibiotics may therefore be used.
For complicated or systemic UTI, treatment must account for severity, structural abnormalities, obstruction, urinary catheters, previous resistant organisms, and previous antibiotic exposure. IDSA recommends a structured approach based on severity, resistance risk, patient-specific factors, and—particularly in sepsis—local antibiogram data.
This distinction is clinically essential because an antibiotic that is highly effective for bladder infection may be inadequate for renal infection.
19. Antibiotic Resistance and Antimicrobial Stewardship
Antimicrobial resistance is increasingly important in the treatment of UTI. Repeated exposure to antibiotics can select resistant organisms, making subsequent infections more difficult to treat.
Antimicrobial stewardship involves using the right antibiotic, at the right dose, by the right route, for the shortest effective duration, while avoiding unnecessary broad-spectrum treatment. The 2025 IDSA complicated-UTI guideline emphasizes narrowing empiric therapy to targeted treatment once urine culture and susceptibility results become available.
Fluoroquinolones and carbapenems are particularly important to preserve because they may be needed for resistant infections. Similarly, unnecessarily prolonged use of third-generation cephalosporins can select for ESBL-producing organisms.
The 2026 IDSA guidance specifically recommends avoiding fluoroquinolones for uncomplicated resistant cystitis when an effective preferred option such as nitrofurantoin or TMP-SMX is available.
Self-medication with leftover antibiotics should be avoided because symptoms such as dysuria may have causes other than bacterial UTI, and inappropriate antibiotic selection can delay correct diagnosis while promoting resistance.
20. Duration of Antibiotic Therapy
The duration of treatment depends on the type of UTI, selected antimicrobial, patient characteristics, response to therapy, and whether the infection is localized or systemic.
Short courses are generally preferred for uncomplicated cystitis when supported by clinical evidence. For example, the EAU guideline lists a single dose of fosfomycin, a five-day course of nitrofurantoin, and three-to-five days of pivmecillinam as commonly recommended regimens for women with cystitis.
Complicated and systemic infections require individualized treatment. The 2025 IDSA guideline recommends shorter courses in clinically improving complicated UTI, suggesting 5–7 days for fluoroquinolones or 7 days for non-fluoroquinolone antibiotics in many patients, while noting that important populations were excluded from many supporting trials and may require individualized treatment.
Longer treatment may be necessary in selected patients, including those with persistent infection, inadequate source control, certain forms of prostatitis, urinary obstruction, abscesses, or other complicating factors.
Antibiotics should not automatically be continued simply because the patient previously received a longer course. Treatment should be based on the clinical syndrome and evidence supporting the chosen duration.
21. Antibiotic Use in Pregnancy
UTI during pregnancy requires particular attention because untreated infection can cause maternal and fetal complications, while some antibiotics have important pregnancy-related safety limitations.
Pregnant patients with suspected UTI should generally be evaluated and treated according to pregnancy-specific guidelines and culture results. The EAU guideline notes that penicillins, cephalosporins, fosfomycin, and selected use of nitrofurantoin may be considered, while trimester-specific restrictions apply to trimethoprim and sulfonamides.
Nitrofurantoin should be avoided in patients with glucose-6-phosphate dehydrogenase deficiency and near the end of pregnancy according to the EAU guideline. Trimethoprim is generally avoided during the first trimester, while sulfonamides should not be used during the last trimester.
Because pregnancy changes both pharmacokinetics and the clinical consequences of UTI, treatment should be selected by a qualified clinician rather than through self-medication.
22. UTI in Patients with Renal Impairment
Renal function is an important consideration when prescribing antibiotics for UTI. Many antimicrobial agents are eliminated partially or predominantly through the kidneys, and impaired renal function may increase drug exposure and toxicity.
Nitrofurantoin is particularly dependent on renal function for achieving effective urinary concentrations. The EAU guideline identifies eGFR below 30 mL/min/1.73 m² as a contraindication because of increased adverse effects and reduced urinary effectiveness.
Aminoglycosides require particular caution because they can cause nephrotoxicity. Patients receiving these agents may require careful renal monitoring and, depending on the drug and treatment strategy, therapeutic drug monitoring.
Other antibiotics may require dose adjustment according to renal function. Therefore, serum creatinine and estimated GFR should be reviewed when clinically appropriate, especially in elderly patients, patients with known kidney disease, and patients receiving potentially nephrotoxic medications.
23. Symptomatic Treatment Alongside Antibiotics
Antibiotics target the underlying bacterial infection, whereas supportive treatment focuses on symptom relief and maintaining adequate hydration when appropriate.
Common symptoms of cystitis include dysuria, urinary frequency, urgency, suprapubic discomfort, and occasionally hematuria. Analgesic therapy may be used when appropriate to reduce discomfort.
The EAU guideline also recognizes that non-antibiotic approaches can reduce antibiotic use in selected patients with cystitis, although these approaches require appropriate patient selection and shared decision-making because symptom burden and risk of progression must be considered.
Symptomatic treatment should not be used to mask signs of systemic infection. Fever, flank pain, vomiting, rigors, hypotension, confusion, or significant deterioration requires medical assessment because the patient may have progressed beyond localized cystitis.
24. Follow-Up After UTI Treatment
Routine urine cultures are generally not necessary in patients whose symptoms resolve completely after treatment for uncomplicated cystitis. The EAU guideline states that routine post-treatment urinalysis or urine cultures are not indicated in asymptomatic patients.
However, additional evaluation becomes important when symptoms persist, recur shortly after treatment, or worsen. In women whose symptoms fail to resolve by the end of treatment or recur within two weeks, the EAU guideline recommends urine culture and antimicrobial susceptibility testing.
Treatment failure may result from antimicrobial resistance, inadequate adherence, an incorrect diagnosis, inadequate drug exposure, urinary obstruction, renal or perinephric abscess, persistent infection, or an underlying structural abnormality.
For recurrent or complicated infections, further evaluation may therefore be required rather than repeatedly prescribing empirical antibiotics.
25. Recurrent UTI and Antibiotic Prophylaxis
Recurrent cystitis is generally defined as at least three episodes within one year or two episodes within six months. Management involves identifying modifiable risk factors, confirming infection when appropriate, and considering non-antibiotic and antibiotic preventive strategies.
When recurrent episodes continue despite behavioral and non-antimicrobial measures, low-dose antimicrobial prophylaxis may be considered in carefully selected patients. The EAU guideline lists regimens such as low-dose nitrofurantoin, trimethoprim, and intermittent fosfomycin in selected circumstances. Post-coital prophylaxis can also be considered when recurrent episodes are temporally associated with sexual activity.
Long-term prophylaxis should not be started casually because prolonged antibiotic exposure can produce adverse effects and promote resistant organisms. The decision should consider recurrence frequency, previous cultures, antibiotic susceptibility, adverse-effect risk, patient preferences, and alternative preventive strategies.
The goal is not simply to prescribe more antibiotics but to reduce the frequency of symptomatic infections while minimizing antimicrobial exposure.
26. Important Clinical Distinction Between Cystitis and Pyelonephritis
One of the most important principles in UTI pharmacotherapy is that not every antibiotic that treats cystitis can treat pyelonephritis.
Nitrofurantoin and oral fosfomycin are excellent examples. They can achieve effective concentrations in urine and are useful for selected lower urinary infections, but they should not be relied upon for renal parenchymal infection. The EAU guideline explicitly recommends against their use for pyelonephritis.
A patient with dysuria and frequency without systemic symptoms may therefore receive a lower-tract regimen, whereas a patient with fever and flank pain requires an antimicrobial capable of reaching renal tissue and systemic circulation.
This distinction prevents an important treatment error: choosing an antibiotic based solely on its ability to concentrate in urine rather than considering where the infection is actually located.
27. Important Adverse Effects of Common UTI Antibiotics
Each antibiotic used in UTI treatment has its own adverse-effect profile.
Nitrofurantoin may cause gastrointestinal intolerance and, rarely, pulmonary, hepatic, or neurological toxicity.
TMP-SMX may cause rash, hyperkalemia, renal effects, cytopenias, and severe hypersensitivity reactions.
Fosfomycin commonly causes gastrointestinal adverse effects, particularly diarrhea and nausea.
Ciprofloxacin and levofloxacin can cause gastrointestinal and neurological adverse effects and are associated with important rare but serious reactions involving tendons, peripheral nerves, cardiac electrophysiology, and other systems.
Amoxicillin-clavulanate commonly causes diarrhea and gastrointestinal discomfort and may produce allergic reactions.
Cephalosporins may cause diarrhea, rash, allergic reactions, and other β-lactam-associated adverse effects.
Aminoglycosides can cause nephrotoxicity and ototoxicity.
Carbapenems can cause gastrointestinal symptoms, hypersensitivity reactions, and, rarely, neurological toxicity such as seizures.
Piperacillin-tazobactam may cause gastrointestinal effects, hypersensitivity reactions, electrolyte disturbances, and other laboratory abnormalities.
Recognizing these adverse effects is important when selecting therapy, particularly in elderly patients, pregnant patients, patients with kidney disease, and those taking multiple medications.
28. Factors Influencing the Choice of UTI Drug
The choice of antimicrobial should be individualized rather than based solely on the name of the infection. Important considerations include:
- Site of infection
- Localized versus systemic presentation
- Severity of illness
- Previous urine-culture results
- Antimicrobial susceptibility
- Local resistance patterns
- Previous antibiotic exposure
- Renal function
- Hepatic function when relevant
- Pregnancy status
- Drug allergies
- Drug-drug interactions
- Age and comorbidities
- Presence of urinary obstruction
- Presence of a urinary catheter
- Structural abnormalities of the urinary tract
- Risk of resistant organisms
- Ability to tolerate oral medication
- Availability and cost of the antibiotic
- Antimicrobial stewardship considerations
The current IDSA approach to complicated UTI specifically emphasizes severity, resistance risk, patient-specific considerations, and local antibiograms in selected patients when choosing empiric therapy.
29. Summary of Major Drugs Used in UTI
| Drug | Main role | Important limitation |
|---|---|---|
| Nitrofurantoin | Uncomplicated cystitis | Not for pyelonephritis |
| TMP-SMX | Cystitis; selected systemic UTI | Resistance and drug interactions |
| Fosfomycin | Uncomplicated cystitis | Not routine therapy for pyelonephritis |
| Ciprofloxacin | Selected pyelonephritis/systemic UTI | Fluoroquinolone adverse effects and resistance |
| Levofloxacin | Selected pyelonephritis/systemic UTI | Fluoroquinolone adverse effects and resistance |
| Amoxicillin-clavulanate | Selected susceptible UTIs | Resistance; broader ecological impact |
| Cefixime | Selected urinary infections | Susceptibility and tissue-penetration considerations |
| Ceftriaxone | Systemic/complicated UTI, pyelonephritis | Parenteral administration |
| Pivmecillinam | Cystitis | Limited role in pyelonephritis |
| Aminoglycosides | Severe/resistant Gram-negative UTI | Nephrotoxicity and ototoxicity |
| Carbapenems | Serious resistant UTI | Broad spectrum; stewardship concerns |
| Piperacillin-tazobactam | Selected complicated/systemic UTI | IV therapy and resistance considerations |
The exact antibiotic and dose should always be selected according to the patient's clinical presentation, culture and susceptibility results when available, renal function, allergies, pregnancy status, and applicable local guidelines. Current international guidance continues to emphasize targeted therapy and avoidance of unnecessary broad-spectrum antibiotics.
.jpeg)
